Policy and legislative efforts to address the threat FDA GLP-1 compounding guidance: In April, the FDA reiterated that state-licensed 503A pharmacies may only compound for individual needs without copying commercial drugs and that federally-registered 503B outsourcing facilities are limited to bulk compounding substances on the 503B bulks or drug shortage lists
L-carnitine may affect warfarin therapy and increase seizure risk at high doses
Fortunately, B12 supplementation can help to improve these symptoms, with improvement typically seen within days to weeks
Alcohol affects blood sugar directly and for people managing type 2 diabetes or metabolic issues, that interaction is clinically meaningful
April 2025: the Trump administration halted that Biden-era push to expand Medicare coverage for weight-loss drugs like Wegovy (semaglutide) and Zepbound (tirzepatide)
Effectiveness depends on which of the available drugs are taken, with tirzepatide seeing higher weight loss than semaglutide and older GLP-1s